In conclusion, gefitinib followed by osimertinib may be a safe and effective treatment option for EGFR mutation–positive NSCLC patients with a poor ECOG PS due to Trousseau syndrome. This evidence concerns the gene EGFR and non-small cell lung carcinoma.